BCT194

DRUG2 trials

Sponsors

Novartis, Novartis Pharmaceuticals

Conditions

Psoriasis

Phase 1

Study of the Safety, Tolerability and Efficacy of BCT194 in Healthy Volunteers and Patients With Psoriasis.

CompletedNCT00417820

NovartisPsoriasis

Start: 2006-11-30End: 2007-11-30Target: 35Updated: 2007-11-29

Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic Patients

CompletedNCT01539915

Novartis PharmaceuticalsPsoriasis

Start: 2007-04-30Updated: 2012-02-28